CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop an innovative mucosal vaccine for tuberculosis, targeting both systemic and mucosal immune responses. It focuses on improving vaccine design and delivery to enhance protection against Mycobacterium tuberculosis, particularly in adults.
Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year.
The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults.
Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis (MTB) infection.
Effective prophylactic vaccination remains the key long-term strategy for combatin…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Sweden, Stockholm
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Spain, Vigo Pontevedra
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Germany, Braunschweig
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
